Maysoun Shomali

RAD1901

F. Μ. Garner, Maysoun Shomali, Dotty Paquin et al. · Anti-Cancer Drugs · 2015 · 158 citations · Full text

Breast Oncology, Estrogen Production, Medicine +11

Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer

Youssef El‐Ahmad, Michel Tabart, Frank Halley et al. · Journal of Medicinal Chemistry · 2019 · 80 citations · Full text

Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) <b>RAD140</b>

Chris P. Miller, Maysoun Shomali, C. Richard Lyttle et al. · ACS Medicinal Chemistry Letters · 2010 · 70 citations · Full text

Pharmacotherapy, Molecular Pharmacology, Medicinal Chemistry +16

SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Maysoun Shomali, Jane Cheng, Fangxian Sun et al. · Molecular Cancer Therapeutics · 2020 · 66 citations · Full text

Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats

Hila Bahar, Kyla Gallacher, Julie Downall et al. · Calcified Tissue International · 2016 · 44 citations · Full text

Bone Health, Six Weeks, Daily Abaloparatide Treatment +9